HRS-8080 + SHR-A2009

HRS-8080 + SHR-A2009 is an experimental **combination therapy** for unresectable or metastatic breast cancer, currently in clinical development. **HRS-8080** is a novel, potent, selective oral estrogen receptor (ER) degrader (SERD), which induces degradation of the estrogen receptor, leading to inhibition of ER activity and subsequent downstream signaling, aimed at suppressing the proliferation of ER-positive and ER-mutated breast cancer cells. **SHR-A2009** is an anti-tumor therapy also investigated for advanced breast cancer; public details on its modality and precise mechanism are limited, but it is being tested directly in combination with HRS-8080. The combination is in multicenter phase I/II clinical trials to assess safety, pharmacokinetics, and anti-cancer efficacy in women with unresectable or metastatic breast cancer.